Expert Perspectives in NET

Hagen Kennecke, a medical oncologist and professor of medicine at Oregon Health Sciences University, discusses the efficacy of cabozantinib in patients with advanced neuroendocrine tumors, specifically in relation to progression-free survival.

Dr. Hagen Kennecke discusses the use of cabozantinib in the treatment of patients with NET who progressed on prior therapies.

Dr. Vijayvergia emphasizes the importance of patient-physician communication and patient education when treating neuroendocrine tumors.